指南与共识鼻科

成人鼻窦炎临床实践指南更新执行摘要

Executive Summary of the Clinical Practice Guideline on Adult Sinusitis Update.
指南 / 共识 · Otolaryngol Head Neck Surg · 2025-01-01

美国耳鼻咽喉头颈外科学会发布了成人鼻窦炎更新版临床实践指南,本执行摘要总结其依据、目的和关键行动声明。指南包含14条推荐,涉及成人鼻窦炎的诊断准确性、辅助检查(影像、鼻内镜、CT、过敏和免疫功能检测)的合理使用以及全身和局部治疗的审慎应用,并强调识别哮喘、囊性纤维化、免疫受损和纤毛运动障碍等可能改变管理的慢性疾病。

要点

  • 更新指南基于14部指南、194篇系统综述和133项随机对照试验的新证据。
  • 观察等待(不用抗生素)扩展至所有无并发症急性细菌性鼻窦炎患者,不论严重程度。
  • 急性细菌性鼻窦炎一线抗生素改为阿莫西林(可联合克拉维酸),而非单用阿莫西林。

核心结论

  • 美国耳鼻咽喉头颈外科学会发布了成人鼻窦炎更新版临床实践指南,包含14条推荐,涵盖诊断准确性、辅助检查的合理使用以及全身和局部治疗的审慎应用。
  • 更新指南强调识别哮喘、囊性纤维化、免疫受损状态、纤毛运动障碍和阿司匹林加重性呼吸疾病等可能改变鼻窦炎管理的慢性疾病。

研究设计与样本

  • 指南由美国耳鼻咽喉头颈外科学会制定,更新组代表耳鼻咽喉头颈外科、感染病科、家庭医学、过敏与免疫学、高级实践护理及消费者倡导等领域。
  • 指南制定采用已发表的55页方案(美国耳鼻咽喉头颈外科学会临床实践指南制定手册第3版),涵盖当前数据评估、主题优先排序、关键行动声明制定、价值判断应用及相关程序。
  • 本次更新基于14部指南、194篇系统综述和133项随机对照试验的新证据,并增加了消费者参与。

主要发现

  • 与2015年版指南相比,观察等待(不用抗生素)作为初始管理策略扩展至所有无并发症急性细菌性鼻窦炎患者,不论严重程度,而非仅限「轻度」患者。
  • 急性细菌性鼻窦炎一线抗生素推荐改为阿莫西林(可联合或不联合克拉维酸),而非既往指南的单用阿莫西林。
  • 新增阿司匹林加重性呼吸疾病(AERD)作为改变慢性鼻窦炎(CRS)管理的慢性疾病。
  • 新增3条关于慢性鼻窦炎管理的关键行动声明,聚焦生物制剂使用(无鼻息肉患者不推荐使用,有鼻息肉患者应进行教育)以及反对仅因第三方手术或影像要求而经验性使用抗生素。
  • 澄清了急性细菌性鼻窦炎诊断、保守管理和抗生素治疗的建议时间线。

关键数值与推荐

  • 14条推荐涉及成人鼻窦炎诊断准确性、辅助检查(包括X线摄影、鼻内镜、计算机断层扫描以及过敏和免疫功能检测)的适当使用,以及全身和局部治疗的审慎使用。
  • 观察等待(不用抗生素)作为初始管理策略适用于所有无并发症急性细菌性鼻窦炎患者,不论严重程度。
  • 急性细菌性鼻窦炎一线抗生素为阿莫西林,可联合或不联合克拉维酸。
  • 对于无鼻息肉的慢性鼻窦炎患者,不推荐使用生物制剂;对于有鼻息肉的患者,应进行生物制剂相关教育。
  • 反对仅因第三方手术或影像要求而经验性使用抗生素治疗慢性鼻窦炎。

临床怎么用

  • 临床应按照更新指南对成人鼻窦炎进行诊断准确性评估,合理使用X线摄影、鼻内镜、CT以及过敏和免疫功能检测等辅助检查以确认诊断和指导管理。
  • 对于无并发症急性细菌性鼻窦炎患者,不论严重程度,均可将观察等待(不用抗生素)作为初始管理策略。
  • 急性细菌性鼻窦炎一线抗生素选择阿莫西林,可联合或不联合克拉维酸。
  • 管理慢性鼻窦炎时应识别哮喘、囊性纤维化、免疫受损状态、纤毛运动障碍和阿司匹林加重性呼吸疾病等可能改变管理的慢性疾病。
  • 无鼻息肉患者不推荐使用生物制剂,有鼻息肉患者应接受生物制剂相关教育;反对仅因第三方手术或影像要求而经验性使用抗生素治疗慢性鼻窦炎。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The American Academy of Otolaryngology-Head and Neck Surgery Foundation has published the updated "Clinical Practice Guideline: Adult Sinusitis" as a supplement to this issue of Otolaryngology-Head and Neck Surgery. To assist in implementing the guideline recommendations, this article summarizes the rationale, purpose, and key action statements. The 14 developed recommendations address diagnostic accuracy for adult rhinosinusitis, the appropriate use of ancillary tests to confirm diagnosis and guide management (including radiography, nasal endoscopy, computed tomography, and testing for allergy and immune function), and the judicious use of systemic and topical therapy. Emphasis was also placed on identifying multiple chronic conditions that would modify management of rhinosinusitis, including asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. An updated guideline is needed as a result of new clinical trials, new systematic reviews, and the lack of consumer participation in the initial guideline development group. METHODS: This executive summary describes the guideline developed using the 55-page protocol published as the American Academy of Otolaryngology-Head and Neck Surgery Foundation's Clinical Practice Guideline Development Manual (3rd edition), which summarizes the methodology for assessments of current data, topic prioritization, development of key action statements, application of value judgements, and related procedures. The guideline update group represented the disciplines of otolaryngology-head and neck surgery, infectious disease, family medicine, allergy and immunology, advanced practice nursing, and a consumer advocate. DIFFERENCES FROM PRIOR GUIDELINE: This clinical practice guideline is as an update, and replacement, for an earlier guideline published in 2015 by the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF).1 An update was planned for 5 years after the initial publication date and was further necessitated by new primary studies and systematic reviews that might suggest a need for modifying clinically important recommendations.2 Changes in content and methodology from the prior guideline include the following: New evidence from 14 guidelines, 194 systematic reviews, and 133 RCTs. Emphasis on patient education and counseling with new explanatory tables. Expanded action statement profiles to explicitly state quality improvement opportunities, confidence in the evidence, intentional vagueness, and differences of opinion. Enhanced external review process to include public comment and journal peer review. New algorithm to clarify decision making, watchful waiting, action statement relationships. Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhinosinusitis (ABRS) regardless of severity, not just patients with "mild" illness (prior guideline). Clarified the recommended timeline for the diagnosis, conservative management and antibiotic treatment of ABRS. Change in recommendation to first-line antibiotic therapy for ABRS amoxicillin, with or without clavulanate, from amoxicillin alone (prior guideline). Addition of aspirin exacerbated respiratory disease (AERD) as a chronic condition that modifies management of chronic rhinosinusitis (CRS). Three new key action statements on managing CRS that focus on the use of biologics (recommend against when patients do not have polyps and educate patients about them when they do) and a recommendation against the empiric use of antibiotics for CRS solely as a third-party requirement for surgery or imaging.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Payne SC, McKenna M, Buckley J, et al. Executive Summary of the Clinical Practice Guideline on Adult Sinusitis Update. Otolaryngol Head Neck Surg. 2025. PMID: 40741969. doi:10.1002/ohn.1342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。